Shanghai Henlius Biotech חוב 2024

מה עושה Shanghai Henlius Biotech?

Shanghai Henlius Biotech Inc. was founded in 2010 and has since focused on the development of innovative biopharmaceuticals. The company is headquartered in Shanghai, China and has additional locations in Taiwan, the USA, and Europe. The company has developed a wide portfolio of products that are manufactured based on monoclonal antibodies. These antibodies are produced in the human body and can recognize and attack diseased tissue, making them useful for the treatment of various diseases. Shanghai Henlius Biotech Inc.'s business model is based on an extensive research and development process, ranging from the discovery of a new drug to final product approval. The company utilizes advanced technologies and research facilities to develop innovative therapies. The company specializes in the development of biosimilars and novel biopharmaceuticals. Biosimilars are drugs that are structurally similar to already approved biopharmaceuticals but may differ in some characteristics, such as their precise molecular structure. The company has already launched several biosimilars on the market, including those for the treatment of gynecologic cancer, breast cancer, and rheumatoid arthritis. In addition to biosimilars, the company also focuses on the development of novel biopharmaceuticals. These drugs are typically used for the treatment of rare diseases or cancer where there are limited treatment options available. The company has developed several such products, including antibodies for the treatment of lung cancer and bladder cancer. Shanghai Henlius Biotech Inc. has successfully established itself in the Chinese market in recent years but also operates internationally. The company has partnerships with numerous companies in Asia, Europe, and the USA to distribute its products worldwide. Partners include well-known names such as Accord Healthcare, Sandoz, and Pfizer. Overall, Shanghai Henlius Biotech Inc. is a leading player in the biotechnology industry. The company specializes in the development of high-quality biopharmaceuticals and has the capability to develop and bring innovative therapies to the market. Its business model is based on extensive research and development processes, allowing the company to be innovative and successful in a highly competitive market. Shanghai Henlius Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.